Eliyahu Sharon Kalif - Mar 5, 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: EVP, Chief Financial Officer
Signature: /s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif
Stock symbol: TEVA
Transactions as of: Mar 5, 2025
Transactions value $: $0
Form type: 4
Date filed: 3/7/2025, 04:19 PM
Previous filing: Mar 6, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TEVA	Ordinary Shares	Options Exercise		+21.4K	+4.89%		459K	Mar 5, 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Options Exercise	$0	-21.4K	-100%	$0.00	0	Mar 5, 2025	Ordinary Shares	21.4K		Direct	F1, F2, F3
transaction	TEVA	Restricted Share Units	Award	$0	+79.7K		$0.00	79.7K	Mar 5, 2025	Ordinary Shares	79.7K		Direct	F1, F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3	Restricted share units were granted on March 5, 2021, with 21,387 vested on each of March 5, 2022, March 5, 2023, March 5, 2024, and 21,390 vested on March 5, 2025.
F4	Restricted share units were granted on March 5, 2025, with 19,916 vesting on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029.